Table 1
Demographic and clinical characteristics of patients and ADRB2 genotype distribution.
| Age in years (mean±SD) | 11.9±2.7 |
|---|---|
| Gender (%) | M: 59.3; F: 40.7 |
| FEV1 before salbutamol (%) (mean±SD) | 87.1±11.3 |
| FEV1 after salbutamol (%) (mean±SD) | 98.8±9.1 |
| Asthma severity: n (%) mild moderate severe | 23 (42.6) 14 (25.9) 17 (31.5) |
| Atopic dermatitis: n (%) | 43 (79.6) |
| Serum IgE (IU/mL) (mean±SD) | 143.3±49.5 |
| Blood eosinophils (%) (mean±SD) | 6.3±2.1 |
| Allele +46A>G: n (%) A G | 45 (41.7) 63 (58.3) |
| Allele +79C>G: n (%) C G | 83 (76.9) 25 (23.1) |
| Genotype +46A>G: n (%) AA GA GG | 13 (24.1) 19 (35.2) 22 (40.7) |
| Genotype +79C>G: n (%) CC CG GG | 34 (63.0) 15 (27.8) 5 (9.2) |
Table 2
Comparison of response to salbutamol, severity of the disease and clinical characteristics between carriers of different ADRB2 genotypes.
| +46A>G | AA | GA | GG | p Value |
|---|---|---|---|---|
| dFEV1 (%) (mean±SD) | 9.4±6.2 | 10.4±5.8 | 14.4±6.1 | 0.044 |
| Asthma severity: n (%) | ||||
| mild | 1 (4.3) | 10 (43.5) | 12 (52.2) | |
| moderate | 8 (57.2) | 3 (21.4) | 3 (21.4) | 0.010 |
| severe | 4 (27.9) | 6 (35.3) | 7 (41.2) | |
| Atopic dermatitis: n (%) | 12 (27.9) | 13 (30.2) | 18 (41.9) | 0.244 |
| Eosinophils in peripheral blood (%) (mean±SD) | 6.0±2.5 | 6.3±1.7 | 6.4±2.3 | 0.600 |
| Serum IgE (IU/mL) (mean±SD) | 152.4±47.5 | 128.0±53.3 | 148.9±49.9 | 0.440 |
| +79C>G | CC | CG | GG | p Value |
|---|---|---|---|---|
| dFEV1 (%) (mean±SD) | 11.6±5.9 | 11.7±7.2 | 13.2±7.5 | 0.955 |
| Asthma severity: n (%) | ||||
| mild | 12 (52.2) | 8 (34.8) | 3 (13.0) | |
| moderate | 12 (85.7) | 2 (14.3) | 0 (0.0) | |
| severe | 10 (58.8) | 5 (29.4) | 2 (11.8) | 0.316 |
| Atopic dermatitis: n (%) | 26 (60.5) | 13 (30.2) | 4 (9.3) | 0.716 |
| Eosinophils in peripheral blood (%) (mean±SD) | 5.9±1.9 | 7.1±1.9 | 6.2±3.4 | 0.089 |
| Serum IgE (IU/mL) (mean±SD) | 141.2±45.9 | 134.4±64.7 | 172.8±42.4 | 0.543 |